article thumbnail

Could CBN really help you sleep? Consumer study data suggest yes.

The Cannigma

CBN has made headlines and claimed shelf space as the next best cannabinoid for sleep. MoreBetter, creators of the Releaf App, is using this real world data to push back against the claim that there’s no evidence that CBN can help people sleep. It also, allegedly, helps with sleep (more on that below). Back to our study.

Sleep 133
article thumbnail

Tryp Therapeutics Announces Phase 2a Clinical Trial for Fibromyalgia with the University of Michigan

Cannabis Law Report

The study is expected to be the world’s first Phase 2a clinical trial evaluating the efficacy of psilocybin and psychotherapy to treat fibromyalgia. The open-label Phase 2a clinical trial will evaluate the efficacy of TRYP-8802, an oral formulation of synthetic psilocybin, in tandem with psychotherapy for treating fibromyalgia.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Cannabis 3.0 Accelerates Access to Consumer and Medical Research

Cannabis Law Report

Virtual Clinical Trials transcend geographic, mobility and economic barriers. Clinical trials are medical research projects involving human participants. However, the costs of conducting a full-scale clinical trial can be prohibitive, posing barriers to research for cannabis companies.

article thumbnail

Press Release: Optimi Health Finalizes Psilocybin Supply Agreement With Bloom Psychedelic Therapy And Research Centre

Cannabis Law Report

Their position as therapeutic practitioners, as well as their work in conducting the kind of clinical trials necessary to advance regulatory outcomes for psychedelic medicines, make them ideal partners in alignment with Optimi’s strategic goals.”. VANCOUVER, British Columbia, July 13, 2022 (GLOBE NEWSWIRE) — Optimi Health Corp. (

Therapy 52
article thumbnail

Ketamine One Advances Research Capabilities via Controlled Substance Dealers Licence Application

Cannabis Law Report

The Company and Its Subsidiary KGK Science Have Also Completed the Pre-Qualification Audits of Its Canadian Facilities to Enable Clinical Trials in an Arrangement with Aleafia Health. The audits will enable KGK to conduct clinical trials in the areas of psychedelics and nutraceuticals, among other substances of study.

article thumbnail

cbdMD Therapeutics Releases Research Plan

Cannabis Law Report

(NYSE American: YCBD, YCBDpA), one of the leading, and most highly trusted and recognized CBD companies, announced today that its recently formed division, cbdMD Therapeutics, has initiated talks with one of the leading US cannabinoid research institutes, to identify novel cannabinoids for therapeutic use. About cbdMD, Inc. cbdMD, Inc.

article thumbnail

Press Release: Toronto Addiction Center Gets First-Ever Federal Grant to Study Effects of Magic Mushroom on Depression

Cannabis Law Report

Researchers will explore whether the psychoactive effects are necessary to relieve treatment-resistant depression in adults. It’s clear that alternative treatment options are necessary to combat depression and other mental illnesses, which is where companies developing psychedelic-based treatments like Optimi Health Corp.